Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA clinical hold lifted for AB-101, Arbutus’s oral PD-L1 inhibitor.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA clinical hold lifted for AB-101, Arbutus’s oral PD-L1 inhibitor
- Clinical development can resume, reducing a key regulatory obstacle
- Press release dated October 22, 2026, contains additional program details
Item EX-99.1 · Exhibit EX-99.1
- FDA clinical hold lifted for AB-101, restoring U.S. clinical development eligibility
- AB-101 Phase 1a/1b data showed generally good tolerability and high receptor occupancy in seven cHBV patients
- Two cHBV patients showed hepatitis B surface antigen decline at the 30mg dose
- Arbutus evaluating next development steps, with additional trials and funding needs remaining uncertain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.